Schering Corporation

Merck Sharp + Dohme Corp.

Schering-plough Corporation

Schering Coporation

Mwangi W Mutahi

Robert G Aslanian

Kevin D McCormick

Michael Berlin

Christopher W Boyce

Wing C Tom

Neng-Yang Shih

Stuart B Rosenblum

Pietro Mangiaracina

Daniel M Solomon

Junying Zheng

Pauline C Ting

Manuel De Lera Ruiz

Jianhua Chao

Henry A Vaccaro

Xiaohong Zhu

John J Piwinski

Qingbei Zeng

Jianhua Cao

Joseph A Kozlowski

Ying Huang

Younong Yu

Purakkattle J Biju

Wei Zhou

Walter Won

Michael Y Berlin

Walter S Won

Kevin D Mc Cormick

In its many embodiments, the present invention provides a novel class of heterocyclic derivatives as a2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the a2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein Mis N; X is a bond, optionally substituted alkylene, alkenylene, &#x2014;O&#x2014;, &#x2014;CHN(R)&#x2014;, &#x2014;N(R)CH&#x2014;, &#x2014;N(R)&#x2014;, &#x2014;NHC(O)&#x2014;, &#x2014;OCH&#x2014;, &#x2014;CHO&#x2014;, or &#x2014;S(O)&#x2014;; and Y is &#x2014;(CH)&#x2014;, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;C(&#x2550;NOR)&#x2014; or &#x2014;SO&#x2014;;

Substituted aniline derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

[object Object]

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein:

Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: 

Disclosed are novel compounds of the formula  Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a Hreceptor antagonist.

Non-imidazole compounds

Disclosed are novel compounds of the formula wherein Ris benzimidazolone derivative, Mand Mare optionally substituted carbon or nitrogen, Rincludes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Disclosed are novel compounds of the formula wherein Ris optionally substituted benzimidazolyl or a derivative thereof; Ris optionally substituted aryl or heteroaryl; Mand Mare C(R) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an Hreceptor antagonist.

Benzimidazole derivatives useful as histamine H3 antagonists

Disclosed are novel compounds of the formulawherein Mis CH or N and Mis C(R) or N; Ris optionally substituted indolyl or an aza derivative thereof; Ris optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a Hreceptor antagonist.

Indole derivatives useful as histamine H3 antagonists

Growing community of inventors

Nyeri, Kenya

Mwangi W Mutahi